- Home
- BTAI vs BNGO Comparison
BTAI vs BNGO Comparison
Compare BTAI & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- BNGO
- Stock Information
- Founded
- BTAI 2017
- BNGO 2003
- Country
- BTAI United States
- BNGO United States
- Employees
- BTAI N/A
- BNGO N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- BNGO Biotechnology: Laboratory Analytical Instruments
- Sector
- BTAI Health Care
- BNGO Industrials
- Exchange
- BTAI Nasdaq
- BNGO Nasdaq
- Market Cap
- BTAI 28.7M
- BNGO 24.3M
- IPO Year
- BTAI 2018
- BNGO 2018
- Fundamental
- Price
- BTAI $0.36
- BNGO $0.21
- Analyst Decision
- BTAI Strong Buy
- BNGO Hold
- Analyst Count
- BTAI 4
- BNGO 3
- Target Price
- BTAI $5.00
- BNGO $1.00
- AVG Volume (30 Days)
- BTAI 949.6K
- BNGO 3.0M
- Earning Date
- BTAI 11-14-2024
- BNGO 11-13-2024
- Dividend Yield
- BTAI N/A
- BNGO N/A
- EPS Growth
- BTAI N/A
- BNGO N/A
- EPS
- BTAI N/A
- BNGO N/A
- Revenue
- BTAI $2,276,000.00
- BNGO $33,334,000.00
- Revenue This Year
- BTAI $164.86
- BNGO N/A
- Revenue Next Year
- BTAI $69.74
- BNGO $2.74
- P/E Ratio
- BTAI N/A
- BNGO N/A
- Revenue Growth
- BTAI 83.25
- BNGO N/A
- 52 Week Low
- BTAI $0.35
- BNGO $0.20
- 52 Week High
- BTAI $4.17
- BNGO $2.27
- Technical
- Relative Strength Index (RSI)
- BTAI 32.49
- BNGO 36.83
- Support Level
- BTAI $0.35
- BNGO $0.20
- Resistance Level
- BTAI $0.52
- BNGO $0.28
- Average True Range (ATR)
- BTAI 0.06
- BNGO 0.02
- MACD
- BTAI -0.00
- BNGO 0.00
- Stochastic Oscillator
- BTAI 2.92
- BNGO 16.87
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.